Evidence map›Paper›PMID 21042865›Full record

ArticleMolecular imaging and biology2011

In vivo, dual-modality OCT/LIF imaging using a novel VEGF receptor-targeted NIR fluorescent probe in the AOM-treated mouse model.

Amy M Winkler, Photini F S Rice, Jan Weichsel, Jennifer M Watson, Marina V Backer, Joseph M Backer, Jennifer K Barton

Abstract read
In one paragraph

Article in Molecular imaging and biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Does MutatedCancer prevention research (Philadelphia, Pa.) · 2018
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Optical molecular imaging in the gastrointestinal tract.Gastrointestinal endoscopy clinics of North America · 2013
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Amy M WinklerCollege of Optical Sciences, The University of Arizona, Tucson, AZ 85721, USA. winkleramy@gmail.com
Photini F S Rice
Jan Weichsel
Jennifer M Watson
Marina V Backer
Joseph M Backer
Jennifer K Barton
University of Arizona · USSibtech (United States) · US

Funding

Dual-Modality System for Imaging Colon Cancer in MiceR01CA109385 · NCI · UNIVERSITY OF ARIZONA · PI BARTON, JENNIFER KEHLET · 2004 to 2013
$3.1M
Molecular Targeted Imaging in Colon CancerR43CA132528 · NCI · SIBTECH, INC. · PI BACKER, JOSEPH M · 2007 to 2007
$163k
NCI NIH HHS R01 CA109385NCI NIH HHS R01CA109835NCI NIH HHS R43 CA132528NCI NIH HHS R43CA132528
6 · The paper itself

Abstract

purposeIncreased vascular endothelial growth factor (VEGF) receptor expression has been found at the sites of angiogenesis, particularly in tumor growth areas, as compared with quiescent vasculature. An increase in VEGF receptor-2 is associated with colon cancer progression. The in vivo detection of VEGF receptor is of interest for the purposes of studying basic mechanisms of carcinogenesis, making clinical diagnoses, and monitoring the efficacy of chemopreventive and therapeutic agents. In this study, a novel single chain (sc)VEGF-based molecular probe is utilized in the azoxymethane (AOM)-treated mouse model of colorectal cancer to study delivery route and specificity for disease. PROCEDURES: The probe was constructed by site-specific conjugation of a near-infrared fluorescent dye, Cy5.5, to scVEGF and detected in vivo with a dual-modality optical coherence tomography/laser-induced fluorescence (OCT/LIF) endoscopic system. A probe inactivated via excessive biotinylation was utilized as a control for nonreceptor-mediated binding. The LIF excitation source was a 633-nm He:Ne laser, and red/near-infrared fluorescence was detected with a spectrometer. OCT was used to obtain two-dimensional longitudinal tomograms at eight rotations in the distal colon. Fluorescence emission levels were correlated with OCT-detected disease in vivo. OCT-detected disease was verified with hematoxylin and eosin stained histology slides ex vivo.

resultsHigh fluorescence emission intensity from the targeted probe was correlated with tumor presence as detected using OCT in vivo and VEGFR-2 immunostaining on histological sections ex vivo. The inactivated probe accumulated preferentially on the surface of tumor lesions and in lymphoid aggregate tissue and was less selective for VEGFR-2.

conclusionThe scVEGF/Cy probe delivered via colonic lavage reaches tumor vasculature and selectively accumulates in VEGFR-2-positive areas, resulting in high sensitivity and specificity for tumor detection. The combination of OCT and LIF imaging modalities may allow the simultaneous study of tumor morphology and protein expression for the development of diagnostic and therapeutic methods for colorectal cancer.

Indexed as

LasersSpectroscopy, Near-InfraredAnimalsAzoxymethaneColonDisease Models, AnimalFluorescent DyesImaging, Three-DimensionalMiceMicroscopy, FluorescenceReceptors, Vascular Endothelial Growth FactorTomography, Optical CoherenceAzoxymethaneFluorescent DyesReceptors, Vascular Endothelial Growth Factor

Identifiers

PMID21042865
PMCPMC3085637
OpenAlexW2033564498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.